Who are losers from the COVID-19 vaccine?
A return to normality thanks to a COVID-19 vaccine will highlight those stocks where valuations have been overdone in recent months and could see them struggle.
These would be healthcare stocks which had been providing PPE equipment and ventilators for the outbreak and online shopping, which would lose out as people returned to bricks-and-mortar retail.
Tech disrupters which been rising in share price in expectation of future profits from a digital and contactless COVID-19 world would also be hindered.
AMP Capital Australian equities portfolio manager, Dermot Ryan, said: “With the shift of earnings growth back into real businesses, some of these growth valuations are hard to justify and may push valuation multiples lower as the rate of change of customer adoption turns negative.
“The run up in valuations in tech has been overdone and there are real risks to their stock prices here if revenue trends moderate.”
A vaccine would also inoculate inflation and boost growth which would prompt a rotation of investment out of bonds and into equities that were reasonably valued.
Winners from the vaccine would be travel, energy and banking as they had struggled during the pandemic from factors such as border restrictions, lack of energy demand and weak commodity prices.
“These three poster child value sectors are now so cheap that they might offer high earnings per share growth, as much lower valuations than you can get in the growth side of the market and that is why they can make sustained gains as the virus is forced to retreat.”
AUTHOR
Laura Dew
Recommended for you
Magellan has closed out the financial year with funds under management approaching $40 billion and outlined its estimated performance fees.
First Sentier Investors chief executive, Mark Steinberg, is set to depart the asset manager after seven years.
Metrics Credit Partners has completed the acquisition of Taurus Finance Group and BC Investment Group as it looks to launch consumer lending arm Navalo.
AMP has announced to the ASX that it is being sued by property fund manager Dexus regarding the sale of its real estate and domestic infrastructure equity business.
